Form 4: Medifast CEO Daniel Chard Receives Restricted Stock Units

Medifast CEO Daniel Chard received 45,087 restricted stock units and reported beneficial ownership of Medifast shares, including those held in a family trust.

Summary

• Daniel R Chard, the Chairman & CEO of Medifast Inc., filed a Form 4 with the SEC on March 15, 2024.
• The filing reports a transaction on March 13, 2024, where Chard acquired 45,087 restricted stock units (RSUs) under the 2012 Share Incentive Plan.
• These RSUs will vest in three equal annual installments starting one year from the grant date.
• Each RSU represents the right to receive one share of Medifast common stock.
• Following the reported transaction, Chard directly owns 103,230 shares of Medifast common stock.
• Additionally, 108,598.352 shares are indirectly owned through The Dan and Allyson Family Irrevocable Trust, for which Chard is the Settlor and Investment Trustee.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This type of equity compensation is common for CEOs in publicly traded companies to incentivize performance and align interests with shareholders.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CEO can be viewed positively as it aligns management's interests with shareholder value.
• Employees: The grant of RSUs to the CEO could be viewed positively as it incentivizes the CEO to improve the company's performance, which could benefit employees.

Key Dates